Can Ehlers-Danlos Syndrome (EDS) cause avascular necrosis (AVN) of the hip?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can EDS Cause AVN of the Hip?

No, Ehlers-Danlos Syndrome (EDS) does not directly cause avascular necrosis (AVN) of the hip. However, AVN can occur as a serious iatrogenic complication of treatment for hip instability and congenital hip dislocation, which are common musculoskeletal manifestations of EDS.

Understanding the Relationship Between EDS and Hip Pathology

Primary Hip Problems in EDS

EDS causes hip pathology through connective tissue abnormalities, not through AVN:

  • Congenital hip dislocation occurs frequently in EDS, particularly in arthrochalasia type (aEDS), where bilateral congenital hip dislocations are a defining feature 1
  • Hip instability and recurrent subluxations result from ligamentous laxity and abnormal collagen structure affecting the ligamentum teres, labrum, and joint capsule 2, 3
  • Joint hypermobility is a cardinal feature of EDS, with the Beighton scale used for diagnosis requiring scores ≥5/9 in adults under 50 years 4, 5

AVN as a Treatment Complication, Not a Disease Feature

The critical distinction is that AVN develops as a complication of hip treatment in EDS patients, not from the syndrome itself:

  • Closed reduction under general anesthesia for congenital hip dislocation carries high AVN risk, with 4 of 5 hips developing AVN after closed reduction in one EDS cohort 6
  • Treatment of developmental dysplasia of the hip (DDH) identifies AVN as "the most serious complication of treatment" and "a predictor of poor prognosis" 7
  • Multiple surgical procedures are often required in EDS patients with hip dislocation (averaging 42 procedures in one series), increasing cumulative AVN risk 6

Clinical Implications and Management Approach

Why EDS Patients Are at Higher Risk for Treatment-Related AVN

  • Difficulty achieving and maintaining reduction due to severe ligamentous laxity requires more aggressive interventions 6
  • Tissue fragility complicates surgical technique and healing 3, 8
  • Need for both femoral and innominate osteotomies to maintain reduction increases surgical complexity 6

Surgical Considerations to Minimize AVN Risk

When treating hip pathology in EDS patients:

  • Avoid closed reduction under general anesthesia when possible, given the 80% AVN rate observed in one series 6
  • Plan for open surgical reduction with capsular plication and ligament reconstruction rather than relying on closed techniques 2, 6
  • Use meticulous surgical technique to minimize vascular and tissue trauma, particularly critical in vascular EDS (type IV) 7
  • Consider ligamentum teres reconstruction with allograft for severe hip instability, which has shown positive outcomes at 1-year follow-up 2

Surveillance and Long-term Outcomes

  • Expect multiple procedures: EDS patients with congenital hip dislocation typically require numerous surgical interventions throughout childhood 6
  • Monitor for AVN development: Clinical outcomes may appear satisfactory in 75% of hips, but radiographic outcomes are satisfactory in only 37.5% due to AVN and other complications 6
  • Functional limitations are common: In arthrochalasia EDS, 33% of patients become wheelchair-bound or unable to walk unaided despite treatment 1

Common Pitfalls to Avoid

  • Do not attribute AVN to EDS itself when evaluating hip pain in these patients—investigate treatment history and consider other AVN risk factors (corticosteroids, trauma, alcohol use)
  • Do not assume standard DDH treatment protocols apply to EDS patients without modification for their increased tissue fragility and ligamentous laxity 6
  • Do not overlook vascular EDS (type IV) when planning any surgical intervention, as these patients have extreme vascular fragility requiring specialized surgical approaches 7, 8
  • Do not delay genetic testing to confirm EDS subtype, as this guides surgical planning and risk stratification 4, 5

References

Research

Arthroscopic ligamentum teres reconstruction of the hip in Ehlers-Danlos syndrome: a case study.

Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2015

Guideline

Diagnosis of Ehlers-Danlos Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Ehlers-Danlos Syndrome Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Congenital dislocation of the hip in Ehlers-Danlos syndrome.

Clinical orthopaedics and related research, 1990

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Vascular manifestations in patients with Ehlers-Danlos syndrome.

Archives of surgery (Chicago, Ill. : 1960), 1982

Related Questions

How do connective tissue disorders, such as Ehlers-Danlos syndrome (EDS) or Marfan syndrome (MS), affect hip development in pediatric and adolescent patients, potentially leading to pathological asymmetry in adulthood?
What is the best management approach for a patient with Ehlers-Danlos (EDS) syndrome and avascular necrosis (AVN) of the hip?
What blood tests are used to diagnose Ehlers-Danlos syndrome?
Can Ehlers-Danlos syndrome cause elevated ferritin levels?
What are the considerations for using bupropion (antidepressant) in patients with Ehlers-Danlos syndrome (EDS)?
What is the recommended dose of dicyclomine (anticholinergic medication) for pediatric patients?
What can a kidney and bladder ultrasound show in a patient with symptoms such as pain, difficulty urinating, or blood in the urine?
What is the recommended treatment for a patient with cluster headaches, considering their medical history and potential cardiovascular disease risk?
Does the return of bleeding with a Mirena (levonorgestrel-releasing intrauterine device (IUD)) around 6 years after insertion in a female of reproductive age signal that its effectiveness is waning?
What alternative treatment can be used for a patient with ADHD, ASD, OCD, GAD, and social anxiety disorder, who has experienced adverse side effects from stimulants, bupropion, vilazodone, and escitalopram, and prefers to avoid antipsychotics, to address social flatness, social anxiety, and OCD symptoms?
Is metoprolol (beta blocker) used to manage testing anxiety in patients with a history of panic attacks and respiratory comorbidities such as asthma or Chronic Obstructive Pulmonary Disease (COPD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.